GlassScriptPhysician profile
Kerry C Gusler
NPI 1174044978
$3,231.65
in general payments reported to CMS, 2019-2025
33 companies · $733 in 2025
The $733 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $207 · 2021: $149 · 2022: $443 · 2023: $739 · 2024: $857 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,234 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,233.87 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $459.80 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Abbvie INC. | $430.92 | 2021-2025 | |
| Novo Nordisk INC | $399.48 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $229.00 | 2020-2025 | |
| Astellas Pharma US INC | $155.02 | 2019-2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $140.78 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $129.64 | 2022-2025 | Repatha, Otezla, Repatha |
| Shield Therapeutics INC | $123.04 | 2022-2025 | Accrufer |
| Medtronic, INC. | $117.72 | 2022-2023 | Minimed 770g, Minimed 780g |
| Glaxosmithkline, LLC. | $95.13 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $91.81 | 2022-2024 | Freestyle Libre |
| Corcept Therapeutics | $88.79 | 2022-2023 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $83.46 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $82.73 | 2020-2021 | |
| Axsome Therapeutics, INC. | $61.91 | 2025 | Auvelity |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $58.66 | 2025 | Jatenzo |
| Novartis Pharmaceuticals Corporation | $50.17 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $50.00 | 2019 | |
| Almatica Pharma LLC | $38.84 | 2024 | Loreev Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $37.16 | 2022 | |
| Exact Sciences Corporation | $36.75 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $33.95 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $33.10 | 2024 | Rexulti |
| Verity Pharmaceuticals INC. | $32.85 | 2025 | Tlando |
| Teva Pharmaceuticals USA, INC. | $32.10 | 2023-2025 | Austedo Xr, Austedo Xr |
| Vertex Pharmaceuticals Incorporated | $25.05 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.46 | 2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $19.40 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $16.99 | 2025 | Zoryve |
| Insulet Corporation | $16.55 | 2024 | Omnipod |
| Merck Sharp & Dohme LLC | $14.11 | 2020 | |
| Supernus Pharmaceuticals, INC. | $13.66 | 2022 | |
| Currax Pharmaceuticals LLC | $13.62 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Gusler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.